Advice on healthier choices offered at free event in Scunthorpe
"Our hospitals are always here when you need us, but Fit4Life offers a fun and interactive way to help you make healthier choices that could reduce the need for medical care in the future," she said.The event will include workshops and presentations by NHS experts, Q&A sessions on healthier lifestyles which reduce your risk of disease, information on cancer screening programmes and interactive sessions that will show how AI is influencing modern healthcare.Fit4Life events have also been planned for Castle Hill Hospital in Cottingham, Goole and District Hospital, Diana, Princess of Wales Hospital in Grimsby, and Scunthorpe General Hospital over the coming months.Listen to highlights from Lincolnshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 minutes ago
- Daily Mail
Huge breakthrough for cancer which hits 8,000 Britons a year: 'Treatment could double chances of survival'
Thousands of patients with advanced bladder cancer could survive for twice as long after a new 'groundbreaking' treatment was approved by the NHS. Health chiefs labelled the green light 'one of the most hopeful advances in decades' for people with the disease. It marks the first significant change to treatment of stage 4 bladder cancer—which accounts for one in ten cases—since the 1980s. Patients will be offered a combination of an antibody drug called enfortumab, and pembrolizumab, an immunotherapy drug. It was approved by the National Institute for Health and Care Excellence (Nice) on Wednesday. In trials, patients who took the combined treatment lived for an average of almost three years compared to 16 months in those who received standard, platinum-based chemotherapy. Scientists also measured the amount of time people that survived without their disease getting worse, and found those on the treatment had a progression-free survival time of a year. By comparison, those on standard treatment had a progression-free survival of six months. Three in ten patients also had no evidence of cancer remaining after the treatment, compared with 14.5 per cent of patients receiving standard care. Martyn Hewett, from Stratford in east London, received the treatment at Barts Health NHS Trust, after a surgery to remove his tumours failed. The 75-year-old said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead now. 'Immediately after the operation failed, I asked the doctor what the prognosis was, and he said, "most people in your position live for a year" and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up—and maybe even be around to see him get married.' The treatment is given via an IV infusion to those whose cancer has spread around their body and cannot be surgically removed. The first drug, enfortumab vedotin, directly targets the cancer cells and kills them, while pembrolizumab helps the immune system to recognise and fight any remaining cancer cells. As well as experiencing better survival rates, patients also have fewer harmful side effects. Experts said there had been real 'unmet need' for patients with advanced cancer, which has spread to other parts of the body, with just 29 per cent of those diagnosed with stage four living for a year. Patients will be offered a combination of an antibody drug called enfortumab, and pembrolizumab, an immunotherapy drug It is estimated that 1,250 people a year could benefit from the treatment. Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival. 'This will help thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Helen Knight, director of medicines evaluation at Nice, added: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leaving them struggling to work, travel or maintain physical activity.' Dr Timir Patel, medical director of Astellas UK, which manufactures enfortumab vedotin, said: 'The guidance from NICE is excellent news for patients. Advanced bladder cancer is an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.'
The Independent
an hour ago
- The Independent
Sanex shower gel advert banned over racial stereotype
A Sanex shower gel television advertisement has been banned by the Advertising Standards Authority (ASA) for reinforcing an offensive racial stereotype. The watchdog ruled the ad, which suggested black skin was "problematic" and white skin "superior", must not air again. This followed two complaints that it perpetuated negative stereotypes about darker skin tones. The ad, seen in June, included a voiceover that said: 'To those who might scratch day and night. To those whose skin will feel dried out even by water,' alongside scenes of a black woman with red scratch marks and another covered with a cracked clay-like material. Alongside scenes of a white woman taking a shower with the product, the ad then stated: 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24 hour hydration feel.' The ad ended with on-screen text and the voiceover stating: 'Relief could be as simple as a shower.' Colgate-Palmolive, which owns the Sanex brand, said the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was shown in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity. On that basis, it believed the ad did not perpetuate negative racial stereotypes and was not likely to cause serious or widespread offence. Clearcast, which approves or rejects ads for broadcast on television, said the ad did not perpetuate negative racial stereotypes and instead demonstrated the product's inclusivity. The agency said one model with darker skin was depicted in a 'stylised and unrealistic way' to demonstrate dryness, but her skin tone was otherwise not a focal point. A second model, also with darker skin, was shown with itchy skin, but this was portrayed through scratching visibly healthy skin and the resulting marks, and was therefore more about sensation than any visible skin condition. The ASA said the use of different skin colours was a means of portraying a 'before and after' of the product's use, which created a juxtaposition of black skin shown as itchy, dry and cracked in the 'before' scenes, and white skin shown as smoother skin in the 'after' scenes. The watchdog said: 'The ad was therefore structured in such a way that it was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved. 'We considered that could be interpreted as suggesting that white skin was superior to black skin.' The ASA added: 'Although we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers, we considered that the ad was likely to reinforce the negative and offensive racial stereotype that black skin was problematic and that white skin was superior. 'We concluded that the ad included a racial stereotype and was therefore likely to cause serious offence.' It further told Colgate-Palmolive 'to ensure they avoided causing serious offence on the grounds of race'.
Telegraph
2 hours ago
- Telegraph
NHS rolls out bladder cancer treatment that can double life expectancy
A new treatment for advanced bladder cancer that doubles life expectancy is set for use on the NHS. Experts said it was the most significant advancement in bladder cancer treatment since the 1980s. Patients diagnosed with stage four bladder cancer, which accounts for one in 10 cases, will be offered a combination of an antibody drug called enfortumab, and pembrolizumab, an immunotherapy drug. In trials, patients lived for an average of almost three years compared to 16 months in those who received standard, platinum-based chemotherapy. Experts said there had been real 'unmet need' for patients with advanced cancer, which has spread to other parts of the body, with just 29 per cent of those diagnosed with stage four living for a year. It is estimated that 1,250 people a year could benefit from the treatment. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that this doubled for those on the new treatment from just six months to more than a year. Almost a third also had a so-called 'complete response' which meant there was no detectable trace of the cancer, compared to 14.5 per cent who received chemotherapy. 'A highly promising and effective new drug' Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year. Now, three and a half years later, here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' Following approval from the National Institute for Health and Care Excellence (Nice), the treatment combination will be available for NHS patients in England diagnosed with advanced bladder cancer, who would have been eligible for the platinum-containing chemotherapy. The combination of drugs are given via an IV infusion in hospitals or clinics. Helen Knight, the director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' 'One of the most hopeful advances in decades' Prof Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, the chief executive of the charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
